ADMERA HEALTH

Company Overview

Admera Health is a precision medicine company providing a suite of high-integrity pharmacogenomics (PGx) solutions, biopharmaceutical research services and diagnostic testing. Admera Health, a spinoff from GeneWiz Inc., is developing and marketing NGS-based testing services for personalized medicine and cancer applications. Admera has a test portfolio of NGS-based diagnostics covering oncology, cardiovascular and pharmacogenomics applications.

In 2019, the NGX Bio marketplace was acquired by Admera Health and expanded significantly to include all aspects of NGS-based products, services and solutions with a broad network of partners. The company provides affordable, comprehensive and creative solutions in DNA research of non-human, human and microbial samples for scientists. Admera Health offers the latest technology in NGS and an experienced, high-quality project management team to guide its customers every step of the way. The DNA-seq services offered by the company are extraction service, whole genome sequencing (WGS), whole exome sequencing (WES), whole genome bisulfite sequencing (WGBS), high throughput chromosome conformation capture (Hi-C), metagenomics, HLA typing, transposase-accessible chromatin using sequencing (ATAC-seq), ddRAD-seq or RAD-seq, chromatin immunoprecipitation sequencing (ChIP-seq) and targeted resequencing.

Tests offered include PGxOne Plus, OncoGxOne, AtheroGxOne and CardioGxOne. PGxOne Plus is a 60+ gene PGx test that provides insight into how patients might respond to some medications based on DNA variants that affect pharmacodynamics and pharmacokinetics. Using next-generation molecular biology technologies, the test gives results aligning with FDA sources and guidelines from professional organizations. PGxOne Plus gives an additional tool for making informed drug management decisions to reduce adverse drug reactions and trial-and-error dosing and drug selection. OncoGxOne is a comprehensive molecular test for detecting driver mutations and immunotherapy biomarkers in solid tumors. OncoGxOne is a comprehensive 364 gene NGS assay for profiling all solid tumor types. Input includes both DNA and RNA for optimal fusion detection.

Company's Business Segments

• Genome Sequencing Solutions : This segment includes Genomics, Clinical-Grade Genomics, Transcriptomics, Bioinformatic Analysis, Single-Cell Sequencing, Spatial Transcriptomics, Epigenomics.